Follows people with Parkinson's disease who previously received BRT-DA01 cell therapy
Observes safety and outcomes in people with Parkinson's disease who earlier received BRT-DA01.
Plain-language title generated from the registry record
Registry title: Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 78 years old?
Source: NCT05897957, who can take part
Where in Canada
- Toronto Western HospitalToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BlueRock Therapeutics
- Trial code
- NCT05897957
- Record updated
- 12 April 2024
- Original description
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.Read full original descriptionShow less
Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01, a Human Embryonic Stem Cell-Derived Midbrain Dopaminergic Neuronal Cell Therapy
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.
Inclusion: Subject received BRT-DA01 in Study MSK-DA01-101 (ie, parent study) and will have completed or discontinued the parent study; Subject must be willing and able to provide written informed consent for the BRT-DA0-501 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures.
Exclusion: No exclusion criteria.